| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KDM6A |
| Uniprot No | O15550 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1095-1258aa |
| 氨基酸序列 | KWKLQLHELTKLPAFVRVVSAGNLLSHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEGYWGVLNDFCEKNNLNFLMGSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAIGWCNNIAWNVGPLTACQYKLAVERYEW |
| 预测分子量 | 26.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KDM6A重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Structural basis of histone H3K27 demethylation by UTX/KDM6A*
**作者**：Agger, K. et al.
**摘要**：本研究解析了KDM6A(UTX)重组蛋白的晶体结构，揭示了其催化结构域如何特异性识别并去除组蛋白H3K27位点的三甲基化修饰。通过体外重组蛋白活性实验，阐明了其酶活性的分子机制及与疾病相关突变的影响。
---
2. **文献名称**：*UTX/KDM6A suppresses EMT and chemoresistance in carcinoma by regulating HOXA1 expression*
**作者**：Wang, L. et al.
**摘要**：研究利用重组KDM6A蛋白进行体外功能实验，证明其通过去甲基化作用激活HOXA1基因表达，从而抑制上皮-间质转化(EMT)和肿瘤耐药性，为KDM6A在癌症治疗中的潜在应用提供了依据。
---
3. **文献名称**：*High-throughput screening identifies small molecules that enhance the enzymatic activity of KDM6A*
**作者**：Kim, J.H. et al.
**摘要**：通过表达纯化重组KDM6A蛋白，建立基于荧光的酶活性检测体系，筛选出可增强其去甲基化活性的小分子化合物，为表观遗传失调相关疾病的药物开发提供了新策略。
---
以上文献涵盖结构解析、功能机制及药物筛选方向，均涉及重组KDM6A蛋白的制备与应用。如需具体文献来源，建议通过PubMed或Web of Science检索标题或作者名获取全文。
**Background of KDM6A Recombinant Protein**
KDM6A (lysine demethylase 6A), also known as UTX, is a member of the Jumonji C (JmjC) domain-containing family of histone demethylases. It specifically targets di- and trimethylated lysine 27 on histone H3 (H3K27me2/3), epigenetic marks associated with transcriptional repression. By removing these methyl groups, KDM6A activates gene expression, playing a critical role in regulating developmental processes, cellular differentiation, and tumor suppression.
The KDM6A gene is located on the X chromosome and escapes X-inactivation, contributing to its functional significance in both males and females. It interacts with key chromatin-modifying complexes, such as the Polycomb Repressive Complex 2 (PRC2), to dynamically balance histone methylation states. This balance is essential for maintaining cellular identity and proper embryonic development. Mutations or deletions in KDM6A are linked to various cancers (e.g., renal cell carcinoma, leukemia) and developmental disorders like Kabuki syndrome, underscoring its role as a tumor suppressor and developmental regulator.
Recombinant KDM6A protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, functional form of the enzyme for research. It retains demethylase activity and is widely used to study epigenetic mechanisms, screen for modulators of its enzymatic function, and explore therapeutic strategies targeting H3K27 methylation pathways. Its applications extend to cancer biology, stem cell reprogramming, and the development of epigenetic drugs aiming to restore dysregulated gene expression in diseases.
Overall, KDM6A recombinant protein serves as a vital tool for dissecting chromatin dynamics and advancing precision medicine in oncology and developmental disorders.
×
